Full Text View
Tabular View
No Study Results Posted
Related Studies
Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer
This study has been completed.
Study NCT00743236   Information provided by National Cancer Institute (NCI)
First Received: August 27, 2008   Last Updated: October 21, 2009   History of Changes

August 27, 2008
October 21, 2009
August 2008
October 2009   (final data collection date for primary outcome measure)
  • Creatinine clearance at 1 year [ Designated as safety issue: No ]
  • Estimated glomerular filtration rate (GFR) at 1 year [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00743236 on ClinicalTrials.gov Archive Site
  • Evidence of local or metastatic recurrence [ Designated as safety issue: No ]
  • Cancer-specific survival [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
Same as current
 
Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer
A Phase III Multi-Institutional Randomized Clinical Trial: Effect of Type of Ischemia - Warm vs Cold During Partial Nephrectomy - on Renal Function

RATIONALE: Warm ischemia is the clamping of blood vessels without cooling the kidney. Cold ischemia is the clamping of blood vessels with kidney cooling. It is not yet known whether warm ischemia is more effective than cold ischemia in patients undergoing surgery for stage I kidney cancer.

PURPOSE: This randomized phase III trial is studying warm ischemia to see how well it works compared with cold ischemia during surgery in treating patients with stage I kidney cancer.

OBJECTIVES:

Primary

  • Determine the effect of warm ischemia during partial nephrectomy on long-term renal function in patients with solitary stage I renal cortical tumor and normal contralateral kidney.

Secondary

  • Determine to what degree the contralateral kidney compensates for the damage inflicted on the operated kidney during surgery.
  • Determine the 1-year disease-specific and overall survival of these patients.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo warm ischemia followed by partial nephrectomy.
  • Arm II: Patients undergo cold ischemia followed by partial nephrectomy. Blood and urine samples are collected periodically after nephrectomy to assess renal function.

Patients are followed at 1, 3, 6, 9 , and 12 months after nephrectomy.

Phase III
Interventional
Treatment, Randomized, Single Blind
  • Kidney Cancer
  • Long-term Effects Secondary to Cancer Therapy in Adults
  • Perioperative/Postoperative Complications
  • Urinary Complications
  • Procedure: cold ischemia procedure
  • Procedure: warm ischemia procedure
  • Experimental: Patients undergo warm ischemia followed by partial nephrectomy.
  • Experimental: Patients undergo cold ischemia followed by partial nephrectomy.
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
176
 
October 2009   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of solitary renal cortical tumor

    • Tumor size ≤ 4 cm
  • Candidate for open partial nephrectomy

    • Expected ischemia time < 45 minutes
  • Normal renal function, defined as glomerular filtration rate (GFR) > 60 mL/min
  • No evidence of distant metastasis
  • No evidence of local invasion of adjacent structures, including the adrenal gland
  • No evidence of tumor extension into the renal venous system
  • No evidence of ureteral obstruction on MAG-3 renal scan
  • No family history of renal cancer

PATIENT CHARACTERISTICS:

  • ECOG performance status 0
  • Life expectancy > 5 years
  • No prior malignancy, except for non-melanomatous skin cancer

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00743236
Regulatory Affairs Associate, Wake Forest University Comprehensive Cancer Center
CDR0000612519, CCCWFU-89108
Wake Forest University
National Cancer Institute (NCI)
Study Chair: Joseph A. Pettus, MD Wake Forest University
National Cancer Institute (NCI)
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP